NCT04898894 2026-01-26
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 1 Active not recruiting
Clinical Trials
30 trialsNCT04640779 2026-01-06
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 1 Active not recruiting
NCT02091245 2025-12-02
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT02199665 2025-11-03
SINE
University of Chicago
Phase 1 Completed
NCT04850755 2025-09-25
A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies
National University Hospital, Singapore
Phase 1 Completed
NCT07094464 2025-07-30
Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation
Chinese PLA General Hospital
Phase 1 Active not recruiting
NCT02303392 2025-06-10
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT04811196 2025-05-29
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
University Health Network, Toronto
Phase 1 Completed
NCT03955783 2024-10-26
Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT05952687 2024-03-27
Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors
St. Jude Children's Research Hospital
Phase 1 Withdrawn
NCT04595994 2024-01-23
SeliSarc
Grupo Espanol de Investigacion en Sarcomas
Phase 1 Recruiting
NCT02299518 2023-06-15
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02120222 2023-04-04
KPT-330
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT05093608 2022-10-17
SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT02403310 2022-10-03
A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02471911 2022-04-12
KPT-330+RICE
Weill Medical College of Cornell University
Phase 1 Completed
NCT02384850 2022-04-08
SENTINEL
GSO Global Clinical Research BV
Phase 1 Terminated
NCT03042819 2021-12-09
Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas
University Health Network, Toronto
Phase 1 Completed
NCT02741388 2021-12-07
SELINDA
The Lymphoma Academic Research Organisation
Phase 1 Completed
NCT02485535 2021-05-13
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
University of Chicago
Phase 1 Completed
NCT03212937 2021-04-28
Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma
National Cancer Centre, Singapore
Phase 1 Completed
NCT02269293 2021-04-23
Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03880123 2020-11-27
Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma
Columbia University
Phase 1 Withdrawn
NCT02831686 2020-11-24
A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02078349 2020-09-10
Phase I Study of KPT330 in Asian Patients
National University Hospital, Singapore
Phase 1 Completed
NCT03661515 2020-05-20
FLAGINEXOR
PETHEMA Foundation
Phase 1 Completed
NCT02573363 2020-04-08
Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
University of Chicago
Phase 1 Completed
NCT02212561 2020-03-26
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
St. Jude Children's Research Hospital
Phase 1 Completed
NCT02093403 2017-12-08
Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02283359 2016-01-15
Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated